Recently, the MAT2A inhibitor PF-9366 with high affinity has been described to efficiently block SAM synthesis, allowing for the first time an evaluation of MAT2A as a therapeutic target in MLLr leukemia [18]. This evidence concerns the gene MAT2A and leukemia.